RSS

hereditary angioedema (HAE)

Shire has announced that the European Medicines Agency (EMA) has validated its marketing authorisation application (MAA) for lanadelumab (SHP643) for investigational Hereditary Angioedema (HAE) treatment. more

News

The US Food and Drug Administration (FDA) has approved Haegarda, which is the first C1 Esterase Inhibitor (human) for subcutaneous (under the skin) administration in the prevention of hereditary angioedema (HAE) attacks more

News

Scientists have shown that hereditary angioedema type III — a rare and serious disorder, characterised by painful swellings in the skin and other organs — is caused by a defective blood protein, coagulation factor XII. more

News